FDA+ roundup: Sen. Tillis goes after Biden administration for supporting march-in rights

Sen. Thom Tillis (R-NC) is push­ing back on the Biden ad­min­is­tra­tion’s plans for how it hy­po­thet­i­cal­ly would use its con­tro­ver­sial “march-in” au­thor­i­ty when drug prices be­come too high.

The Biden ad­min­is­tra­tion in De­cem­ber un­veiled a frame­work that laid out how the fed­er­al gov­ern­ment would con­sid­er pric­ing when de­ter­min­ing whether it would take over a patent for a prod­uct that was de­vel­oped us­ing fed­er­al fund­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.